Epigenome-wide analysis across the development span of pediatric acute lymphoblastic leukemia: backtracking to birth.
VTRNA2-1
Birth cohort
DNA methylation
Epigenetics
Neonatal blood spots
Pediatric leukemia
Journal
Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
received:
07
06
2024
accepted:
09
09
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
Cancer is the leading cause of disease-related mortality in children. Causes of leukemia, the most common form, are largely unknown. Growing evidence points to an origin in-utero, when global redistribution of DNA methylation occurs driving tissue differentiation. Epigenome-wide DNA methylation was profiled in surrogate (blood) and target (bone marrow) tissues at birth, diagnosis, remission and relapse of pediatric pre-B acute lymphoblastic leukemia (pre-B ALL) patients. Double-blinded analyses was performed between prospective cohorts extending from birth to diagnosis and retrospective studies backtracking from clinical disease to birth. Validation was carried out using independent technologies and populations. The imprinted and immuno-modulating VTRNA2-1 was hypermethylated (FDR<0.05) at birth in nested cases relative to controls in all tested populations (totaling 317 cases and 483 controls), including European and Hispanic ancestries. VTRNA2-1 methylation was stable over follow-up years after birth and across surrogate, target and other tissues (n=5,023 tissues; 30 types). When profiled in leukemic tissues from two clinical cohorts (totaling 644 cases), VTRNA2-1 methylation exhibited higher levels at diagnosis relative to controls, it reset back to normal levels at remission, and then re-increased to above control levels at relapse. Hypermethylation was significantly associated with worse pre-B ALL patient survival and with reduced VTRNA2-1 expression (n=2,294 tissues; 26 types), supporting a functional and translational role for VTRNA2-1 methylation. This study provides proof-of-concept to detect at birth epigenetic precursors of pediatric pre-B ALL. These alterations were reproducible with different technologies, in three continents and in two ethnicities, and can offer biomarkers for early detection and prognosis as well as actionable targets for therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer is the leading cause of disease-related mortality in children. Causes of leukemia, the most common form, are largely unknown. Growing evidence points to an origin in-utero, when global redistribution of DNA methylation occurs driving tissue differentiation.
METHODS
METHODS
Epigenome-wide DNA methylation was profiled in surrogate (blood) and target (bone marrow) tissues at birth, diagnosis, remission and relapse of pediatric pre-B acute lymphoblastic leukemia (pre-B ALL) patients. Double-blinded analyses was performed between prospective cohorts extending from birth to diagnosis and retrospective studies backtracking from clinical disease to birth. Validation was carried out using independent technologies and populations.
RESULTS
RESULTS
The imprinted and immuno-modulating VTRNA2-1 was hypermethylated (FDR<0.05) at birth in nested cases relative to controls in all tested populations (totaling 317 cases and 483 controls), including European and Hispanic ancestries. VTRNA2-1 methylation was stable over follow-up years after birth and across surrogate, target and other tissues (n=5,023 tissues; 30 types). When profiled in leukemic tissues from two clinical cohorts (totaling 644 cases), VTRNA2-1 methylation exhibited higher levels at diagnosis relative to controls, it reset back to normal levels at remission, and then re-increased to above control levels at relapse. Hypermethylation was significantly associated with worse pre-B ALL patient survival and with reduced VTRNA2-1 expression (n=2,294 tissues; 26 types), supporting a functional and translational role for VTRNA2-1 methylation.
CONCLUSION
CONCLUSIONS
This study provides proof-of-concept to detect at birth epigenetic precursors of pediatric pre-B ALL. These alterations were reproducible with different technologies, in three continents and in two ethnicities, and can offer biomarkers for early detection and prognosis as well as actionable targets for therapy.
Identifiants
pubmed: 39443995
doi: 10.1186/s12943-024-02118-4
pii: 10.1186/s12943-024-02118-4
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
238Informations de copyright
© 2024. The Author(s).
Références
Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol. 2017;18(6):719–31.
doi: 10.1016/S1470-2045(17)30186-9
pubmed: 28410997
pmcid: 5461370
Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541–52.
doi: 10.1056/NEJMra1400972
pubmed: 26465987
Erdmann F, Ghantous A, Schüz J. Environmental agents and childhood cancer. In: Nriagu J, editor. Encyclopedia of Environmental Health. 2nd ed. Burlington: Elsevier B.V.; 2019. p. 336–47. https://scholar.google.com/scholar_lookup?title=Encyclopedia+of+Environmental+Health&author=F+Erdmann&author=A+Ghantous&author=J+Sch%C3%BCz&author=J+Nriagu&publication_year=2019& .
Ghantous A, Hernandez-Vargas H, Byrnes G, Dwyer T, Herceg Z. Characterising the epigenome as a key component of the fetal exposome in evaluating in utero exposures and childhood cancer risk. Mutagenesis. 2015;30(6):733–42.
doi: 10.1093/mutage/gev010
pubmed: 25724893
pmcid: 4757935
Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555(7696):321–7.
doi: 10.1038/nature25480
pubmed: 29489754
Nordlund J, Syvänen AC. Epigenetics in pediatric acute lymphoblastic leukemia. Semin Cancer Biol. 2018;51:129–38.
doi: 10.1016/j.semcancer.2017.09.001
pubmed: 28887175
Nordlund J, Bäcklin CL, Wahlberg P, Busche S, Berglund EC, Eloranta ML, et al. Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia. Genome Biol. 2013;14(9):r105.
doi: 10.1186/gb-2013-14-9-r105
pubmed: 24063430
pmcid: 4014804
Wiemels J. Perspectives on the causes of childhood leukemia. Chem Biol Interact. 2012;196(3):59–67.
doi: 10.1016/j.cbi.2012.01.007
pubmed: 22326931
Greaves M. A causal mechanism for childhood acute lymphoblastic leukaemia. Nat Rev Cancer. 2018;18(8):471–84.
doi: 10.1038/s41568-018-0015-6
pubmed: 29784935
pmcid: 6986894
Xiong Z, Yang F, Li M, Ma Y, Zhao W, Wang G, et al. EWAS Open Platform: integrated data, knowledge and toolkit for epigenome-wide association study. Nucleic Acids Res. 2022;50(D1):D1004–9.
doi: 10.1093/nar/gkab972
pubmed: 34718752
Koch A, Jeschke J, Van Criekinge W, van Engeland M, De Meyer T. MEXPRESS update 2019. Nucleic Acids Res. 2019;47(W1):W561–5.
doi: 10.1093/nar/gkz445
pubmed: 31114869
pmcid: 6602516
Hjalgrim LL, Rostgaard K, Schmiegelow K, Söderhäll S, Kolmannskog S, Vettenranta K, et al. Age- and sex-specific incidence of childhood leukemia by immunophenotype in the Nordic countries. JNCI. 2003;95(20):1539–44.
doi: 10.1093/jnci/djg064
pubmed: 14559876
Carpenter BL, Zhou W, Madaj Z, DeWitt AK, Ross JP, Grønbæk K, et al. Mother-child transmission of epigenetic information by tunable polymorphic imprinting. Proc Natl Acad Sci USA. 2018;115(51):E11970–7.
doi: 10.1073/pnas.1815005115
pubmed: 30509985
pmcid: 6304996
Jeon SH, Johnson BH, Lee YS. A tumor surveillance model: a non-coding RNA senses neoplastic cells and its protein partner signals cell death. Int J Mol Sci. 2012;13(10):13134–9.
doi: 10.3390/ijms131013134
pubmed: 23202942
pmcid: 3497316
Lee YS, Bao X, Lee HH, Jang JJ, Saruuldalai E, Park G, et al. Nc886, a novel suppressor of the type I interferon response upon pathogen intrusion. Int J Mol Sci. 2021;22(4):2003.
doi: 10.3390/ijms22042003
pubmed: 33670458
pmcid: 7922379